Prenatal tests

The test involves the determination of three biochemical compounds in the pregnant woman's serum for the non-invasive screening of the risk of fetal defects, such as Down syndrome (trisomy 21) and open neural tube defects in the second trimester of pregnancy.

Inhibin A levels used in the risk assessment and diagnosis of pregnancy disorders, in the monitoring of high-risk pregnancies, and in the diagnosis and monitoring of treatment of ovarian canceróo cancer.

The PAPP-A test is a prenatal, non-invasive diagnostic test based on the evaluation of the concentration of a specific protein produced in a woman's body during pregnancy. The PAPP-A test makes it possible to estimate the statistical risk of fetal genetic defects in the form of trisomies.

Determination of the free subunit of ß-hCG in the monitoring of malignant diseasesób and for the diagnosis of chromosomal defects of the fetus.

Non-invasive prenatal test from maternal blood, detects trisomies 13, 18 and 21, gender aneuploidies and microdeletions: DiGeorge, Smith-Magenis, Wolf-HirschHorn and 1p36.

VERAgene is non-invasive prenatal testing (NIPT) for aneuploidies, microdeletions and point mutations. The test detects 2,000 mutations as part of a 100 disease screening test.

Panorama test: chromosomes 13, 18, 21, X and Y; triploidy

The Panorama test is a non-invasive, safe, prenatal screening test. The Panorama test is currently the best, that is, the most accurate test on the market. Thanks to the use of unique technology to distinguish the DNA of the baby from the DNA of the mother, the results are reliable. The test also determines the sex of the baby.